reports
Verrica Announces Pricing of $42.0 Million Public Offering
Verrica Announces Pricing of $42.0 Million Public Offering WEST CHESTER, Pa., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the pricing of an underwritten public offering of 44,964,045 shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase 2,235,955 shares of its common stock, and in either case, accompanying Series A warrants to purcha...
Verrica Announces Proposed Public Offering
Verrica Announces Proposed Public Offering WEST CHESTER, Pa., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it intends to offer and sell shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof) and in either case, accompanying warrants to purchase shares of its common stock, in an underwritten public offering. All of the securities in the proposed offering will...
Beyond Air to Participate in the Piper Sandler 36th Annual Healthcare ...
Beyond Air to Participate in the Piper Sandler 36th Annual Healthcare Conference GARDEN CITY, N.Y., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of Nitric Oxide (NO) to improve the lives of patients, today announced that Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, will participate in one-on-one meetings and a fireside chat at the Piper Sandler 36th Annual Healthcare Conference being held December 3-5, 2024 in New York. Fi...
Moody's Ratings announces completion of a periodic review of ratings o...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of Nuveen New Jersey Quality Muni Income Fd and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 11 November 2024 in which we reassessed the appropriateness of the...
First Merchants Corporation Announces Cash Dividend
First Merchants Corporation Announces Cash Dividend MUNCIE, Ind., Nov. 13, 2024 (GLOBE NEWSWIRE) -- First Merchants Corporation declared a cash dividend on November 12, 2024 of $0.35 per share. The dividend is payable on December 20, 2024, to shareholders of record as of December 6, 2024. For purposes of broker trading, the ex-date of the cash dividend is December 5, 2024. About First Merchants Corporation: First Merchants Corporation is a financial holding company headquartered in Muncie, Indiana. The Corporation has one full-service bank charter, First Merchants Bank. The Bank also op...
Beyond Air® Reports Fiscal Second Quarter 2025 Financial Results and P...
Beyond Air® Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update Revenues increased 17% compared to the previous quarter ended June 30, 2024 Strengthened balance sheet is expected to provide sufficient cash runway through June 2026 Completed a $20.6 million private placement offering with multiple healthcare-focused institutional funds and Company insiders Retired $17.5 million in debt from Avenue Capital and entered into a $11.5 million loan agreement with an insider-led investor group Conference call scheduled for 4:30 p.m. ET today, November 11t...
Beyond Cancer Presents Promising Preclinical Data on Low Volume Ultra-...
Beyond Cancer Presents Promising Preclinical Data on Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) Therapy at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting - LV UNO in combination with anti-rPD-L1 resulted in prolonged survival and doubled the tumor growth inhibition rate in MAT B III tumor bearing rats compared to anti-rPD-L1 alone - LV UNO compares favorably to HV UNO administration in reducing tumor volumes in combination with anti-mPD-1 in CT26 BALB/c mice - Increased nitro-tyrosine staining in LV UNO treated tumors indicates an improved dis...
Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results a...
Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition – Company reported $0 in product shipments in the third quarter of 2024 and recognized negative net product revenue of $1.9 million, including a provision for product returns of $1.7 million– – Company expects existing distributor inventory to support most demand for dispensed applicator units into the first quarter of 2025 – – Company continues to look for ways to manage expenses and expand access to YCANTH® for the t...
Beyond Air® Schedules Second Fiscal Quarter 2025 Financial Results Con...
Beyond Air® Schedules Second Fiscal Quarter 2025 Financial Results Conference Call and Webcast GARDEN CITY, N.Y., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients, today announced that it plans to report the financial results for the second quarter of its fiscal year 2025 ended September 30, 2024 on Monday, November 11, 2024 after the market closes. Conference Call & ...
First Merchants Corporation Announces Third Quarter 2024 Earnings per ...
First Merchants Corporation Announces Third Quarter 2024 Earnings per Share MUNCIE, Ind., Oct. 24, 2024 (GLOBE NEWSWIRE) -- First Merchants Corporation (NASDAQ - FRME) Third Quarter 2024 Highlights: Net income available to common stockholders was $48.7 million and diluted earnings per common share totaled $0.84, compared to $55.9 million and $0.94 in the third quarter of 2023, and $39.5 million and $0.68 in the second quarter of 2024. Excluding the loss from repositioning of the available for sale securities portfolio, adjusted net income was $55.6 million or $0.95 per share for the t...
Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featurin...
Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference - Posters to highlight the safety data, tolerability data, and antitumor efficacy data of VP-315 for the treatment of basal cell carcinoma as determined by histological clearance - WEST CHESTER, Pa., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases...
First Merchants Corporation Announces Cash Dividend on Its Preferred S...
First Merchants Corporation Announces Cash Dividend on Its Preferred Stock MUNCIE, Ind., Oct. 15, 2024 (GLOBE NEWSWIRE) -- First Merchants Corporation has declared a quarterly cash dividend of $46.88 per share on its 7.50% Non-Cumulative Perpetual Preferred Stock Series A, represented by depositary shares (NASDAQ: FRMEP) each representing a 1/100th interest in a share of the Series A preferred stock. Holders of depositary shares will receive $0.4688 per depositary share. The dividend will be payable on November 15, 2024, to stockholders of record on October 31, 2024. About First Merchant...
Beyond Cancer to Present Preclinical Data of Ultra-High Concentration ...
Beyond Cancer to Present Preclinical Data of Ultra-High Concentration Nitric Oxide (UNO) Low Volume Therapy at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting Submitted abstracts selected for the annual meeting are scheduled to be released to SITC registrants on Tuesday, November 5th at 9:00 AM U.S. ET Presentations of Beyond Cancer’s two full posters will take place on November 8th and 9th at the SITC Annual Meeting; ePublications of the posters will be available November 7th Therapeutic efficacy of Low Volume (
First Merchants Corporation to Report Third Quarter 2024 Financial Res...
First Merchants Corporation to Report Third Quarter 2024 Financial Results, Host Conference Call and Webcast MUNCIE, Ind., Oct. 03, 2024 (GLOBE NEWSWIRE) -- First Merchants Corporation (Nasdaq:FRME) will report third quarter 2024 financial results on October 24, 2024. The Corporation will host a third quarter 2024 earnings conference call and webcast at 11:30 a.m. (ET) on Thursday, October 24, 2024. To access via phone, participants will need to register using the following link where they will be provided a phone number and access code: () In order to view the webcast and presentation ...
Beyond Air Partners with Healthcare Links to Expand Access to LungFit®...
Beyond Air Partners with Healthcare Links to Expand Access to LungFit® PH System Through Group Purchasing Organizations and Integrated Delivery Networks Revolutionary inhaled nitric oxide technology set to reach broader healthcare systems GARDEN CITY, N.Y., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients, today announced entering a strategic partnership with Health...
Verrica Pharmaceuticals Announces Restructuring of Commercial Organiza...
Verrica Pharmaceuticals Announces Restructuring of Commercial Organization - Company significantly reduces cost structure with a realigned sales, marketing and operational infrastructure - Sales and marketing efforts to focus on pediatricians and expand access beyond dermatologists WEST CHESTER, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced a restructuring of its sales and operating teams to redu...
- Jonathan Moreland
GDOT GREEN DOT CORPORATION CLASS A
TALO TALOS ENERGY INC.
XAIR BEYOND AIR
CTLP CANTALOUPE
BMEA INC.
FTHY BIOMEA FUSION
BIGZ INC.
GTE FIRST TRUST HIGH YIELD OPPORTUNITIES 2027 TERM FUND
BMEZ BLACKROCK INNOVATION AND GROWTH TST
GRAN TIERRA ENERGY INC.
BLACKROCK HEALTH SCIENCES TERM TRUST
Beyond Air Provides LungFit® PH System to U.S. Naval Hospital Guam for...
Beyond Air Provides LungFit® PH System to U.S. Naval Hospital Guam for Neonatal Critical Care in Partnership with TrillaMed GARDEN CITY, N.Y., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, is proud to announce the deployment of its groundbreaking LungFit® PH system to the U.S. Naval Hospital Guam. This partnership, made possible through collaboration with TrillaMed, marks a significant a...
Beyond Air Announces Termination of the Loan and Security Agreements w...
Beyond Air Announces Termination of the Loan and Security Agreements with Avenue Capital – Retiring $17.5 million in Avenue Capital debt and entering into a $11.5 million loan agreement with an insider-led investor group – – Eliminating $12 million in scheduled debt payments through June 2026 – – $11.5 million loan agreement defers payment of principal and interest through June 2026 - – 60% increase in the number of hospital contracts since July 1, 2024, including U.S. Naval Hospital Guam – GARDEN CITY, N.Y., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.